Case Report Peripheral Blood Polyclonal Plasmacytosis Mimicking

Total Page:16

File Type:pdf, Size:1020Kb

Case Report Peripheral Blood Polyclonal Plasmacytosis Mimicking Int J Clin Exp Pathol 2011;4(4):416-420 www.ijcep.com /IJCEP1103011 Case Report Peripheral blood polyclonal plasmacytosis mimicking plasma cell leukemia in patients with angioimmunoblastic T-cell lymphoma: report of 3 cases and review of the literature Arshad N. Ahsanuddin1, Russell K. Brynes2, Shiyong Li1 1Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA and 2Depart- ment of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA Received March 31, 2011; accepted April 12, 2011; Epub April 18, 2011; published April 30, 2011 Abstract: Angioimmunoblastic T-cell lymphoma (AITL) is a unique type of peripheral T-cell lymphoma. Patients with AITL may have occasional reactive plasma cells present in the peripheral circulation. Prominent peripheral blood poly- clonal plasmacytosis mimicking plasma cell leukemia, however, is distinctly uncommon. Here we describe 3 such cases from two large tertiary medical centers and discuss the role of ancillary studies in the differential diagnosis of peripheral blood plasmacytosis. Keywords: Angioimmunoblastic T-cell lymphoma, peripheral blood, plasmacytosis, flow cytometric immunopheno- typing Introduction with moderate amounts of clear cytoplasm and follicular dendritic cell networks. Admixed are Angioimmunoblastic T-cell lymphoma (AILT) is small reactive lymphocytes and occasional large the second most common peripheral T-cell lym- immunoblasts of B-cell lineage, as well as eosi- phoma with a constellation of clinical signs and nophils, histiocytes and plasma cells. In the symptoms including fever, weight loss, chills, bone marrow, the disease is characterized by a skin rash, pruritus, lymphadenopathy, hepa- nodular or interstitial pattern of hypocellular tosplenomegaly, anemia, thrombocytopenia and fibrovascular proliferations, infiltrated by lym- polyclonal hypergammaglobulinemia [1, 2]. It phoid cells, eosinophils and reactive plasma was first described by Frizzera et al in the early cells [4, 5]. 1970s as “angio-immunoblastic lymphad- nopahy with dysproteinemia (AILD),” and was In the peripheral blood, patients with AITL fre- originally thought to be a benign, albeit prema- quently present with anemia, thrombocytopenia lignant, atypical T-cell proliferation [3]. AILD was and absolute lymphopenia. Occasional circulat- reclassified in the Revised European and Ameri- ing plasma cells, plasmacytoid lymphocytes and can classification of Lymphoid neoplasms, and immunoblasts have been reported in about one in the 2008 World Health Organization classifi- third of patients with AITL. Exuberant reactive cation of hematolymphoid neoplasms, as a dis- plasmacytosis mimicking plasma cell leukemia, tinct type of peripheral T-cell lymphoma. however, has only rarely been described [5-7]. Here we present 3 such cases from two large In the lymph node, AITL is characterized by pro- tertiary medical centers, and discuss the differ- liferation of high-endothelial venules sur- ential diagnosis of peripheral blood plasmacyto- rounded by a polymorphous infiltrate of medium sis in light of ancillary studies that are now rou- -sized lymphoid cells of follicular T-cell origin tinely available. Peripheral blood polyclonal plamacytosis in AITL Materials and methods (20%) showing large size, occasional multiple nuclei, small nucleoli, and frequent mitoses. Case report Flow cytometric immunophenotyping Case #1: A 76 year-old woman presented with hypercalcemia, fever and diffuse lymphade- Flow cytometric immunophenotyping was per- nopathy. Serum protein electrophoresis demon- formed as previously described. Intracellular strated hypoalbuminemia and polyclonal hyper- staining for kappa and lambda immunoglobulin gammaglobulinemia. Peripheral blood findings light chains was performed after membrane included an elevated total white blood cell count permeablization. Stained cells were acquired (16,000 cells/µL) with absolute lymphopenia with FACSCanto™ II flow cytometer and the list- (1,600 cells/µL) and normochromic normocytic mode data was analyzed with Diva software (BD anemia (hematocrit 28.6%). The peripheral Biosciences). blood smear demonstrated Rouleaux formation, and numerous circulating plasma cells, plas- Results macytoid lymphocytes and scattered immuno- blasts, accounting for about 30% of all white Review of the peripheral blood smear from all 3 blood cells. Platelets were normal in number patients revealed a prominent population of and appearance. plasma cells, plasmacytoid lymphocytes and immunoblasts (more than 2 x 103 cells/µL or Case #2: A 43 year-old woman had a past medi- 20% of the nucleated cells on manual differen- cal history of AITL status six years post treat- tial). Mitosis is occasionally observed. Rouleaux ment. She was subsequently diagnosed with formation is prominent. Representative images stage IIC ovarian cancer and treated with che- are shown in Figure 1. motherapy, which was stopped early due to de- velopment of idiopathic thrombocytopenic pur- Flow cytometric immunophenotyping of the pe- pura. She presented with hemolytic anemia and ripheral blood from all 3 cases showed that ap- thrombocytopenia refractory to plasmapheresis, proximately 10-30% of the white blood cells intravenous pooled immunoglobulin, and ster- expressed CD19, CD38 (high density) and CD45 oid treatment. She underwent emergent sple- (low density). Other B cells markers including nectomy and was admitted to the Medical Inten- CD20 were negative. CD56 expression was ab- sive Care Unit. sent. Surface and intracytoplasmic light chains showed a mixed pattern of expression, confirm- Peripheral blood findings included an elevated ing the polyclonal nature of the plasma cells white count (18,100 cells/µL) with marked ane- and plasmacytoid lymphocytes. Representative mia (hematocrit 12.7%) and thrombocytopenia scatter plots of the flow cytometric immunophe- (5,000 platelets/µL). The peripheral smear notypic findings are shown in Figure 2. No aber- demonstrated moderate Rouleaux formation rant T-cell populations were detected. Serum with increased numbers of circulating nucleated protein electrophoresis in 2 patients showed red blood cells, plasmacytoid lymphocytes and polyclonal hypergammaglobulinemia. plasma cells. A manual differential count dem- onstrated 63% segmented neutrophils and 6% Molecular assay of the peripheral blood sam- lymphocytes, with 13% plasmacytoid lympho- ples showed a polyclonal pattern for the immu- cytes and plasma cells. noglobulin heavy chain gene and an oligoclonal pattern for the T-cell receptor gamma gene Case #3: A 60 year-old man presented with gen- (data not shown). Lymph node and bone mar- eralized lymphadenopathy and splenomegaly. row biopsies were subsequently performed in all Peripheral blood counts were significant for nor- 3 patients and the morphologic, immunopheno- mochromic, normocytic anemia (hematocrit typic and molecular findings were diagnostic of 27.6%), absolute lymphopenia (700 cells/µL), de novo (cases #1 and #3) and recurrent (case and thrombocytopenia (12,000 platelets/µL). #2) AITL (data not shown). Serum protein electrophoresis demonstrated polyclonal hypergammaglobulinemia. The pe- Discussion ripheral smear demonstrated moderate Rouleaux formation with a marked increase in We report here a prominent peripheral blood plasma cells and plasmacytoid lymphocytes plasmacytosis in 3 patients prior to the diagno- 417 Int J Clin Exp Pathol 2011;4(4):416-420 Peripheral blood polyclonal plamacytosis in AITL sis of de novo or recurrent AITL. All patients had generalized lymphadenopathy and/or splenomegaly. A mixture of plasma cells, plas- macytoid lymphocytes and immunoblasts meet- ing the diagnostic criterion of plasma cell leuke- mia was present in the peripheral blood, as de- termined by smear morphology and manual differential. These cells were polyclonal by flow cytometric immunophenotyping, serum protein electrophoresis, and/or molecular assay for immunoglobulin heavy chain gene rearrange- ment, consistent with a reactive process. No evidence of circulating lymphoma cells was de- tected in the blood samples. Plasma cell leukemia is defined by a neoplastic proliferation of clonal plasma cells in excess of 2 x 103 cells/µL or 20% of the white blood cells in the peripheral blood. The clonality of these cells can be demonstrated by serum protein electrophoresis and/or flow cytometric immuno- phenotyping. In rare cases of nonsecretory plasma cells, molecular studies for immu- noglobulin heavy chain gene rearrangement might be needed. Patients with plasma cell leu- kemia have a dismal prognosis with a median survival less than 1 year in most cases. Figure 1. Representative images of peripheral blood Prominent peripheral blood plasmacytosis mim- film (Wright and Giemsa stain) showing anemia with marked Rouleaux formation (A; 10x) and circulating icking plasma cell leukemia in patients with AITL plasma cells, plasmacytoid lymphocytes and im- was first reported by Pangalis et al in 1978.[8] munoblasts (B; 100x). Among the 38 AITL cases reported, about a third had circulating “immunocytes”, which were defined as plasma cells, plasmacy- toid lymphocytes, and immuno- blasts. One patient demonstrated a prominent plasmacytosis with as many as 32,000 cells/ µL. It has been reported that a variable num- ber of circulating lymphoma cells are present in the peripheral blood in approximately 30% of patients with AITL [9]. It is unclear whether some of these plasmacytoid or immuoblastic cells reported by Pangalis et
Recommended publications
  • Spotlight on Ixazomib: Potential in the Treatment of Multiple Myeloma Barbara Muz Washington University School of Medicine in St
    Washington University School of Medicine Digital Commons@Becker Open Access Publications 2016 Spotlight on ixazomib: Potential in the treatment of multiple myeloma Barbara Muz Washington University School of Medicine in St. Louis Rachel N. Ghazarian Washington University School of Medicine in St. Louis Monica Ou Washington University School of Medicine in St. Louis Micha J. Luderer Washington University School of Medicine in St. Louis Hubert D. Kusdono Washington University School of Medicine in St. Louis See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Muz, Barbara; Ghazarian, Rachel N.; Ou, Monica; Luderer, Micha J.; Kusdono, Hubert D.; and Azab, Abdel K., ,"Spotlight on ixazomib: Potential in the treatment of multiple myeloma." Drug Design, Development and Therapy.2016,10. 217-226. (2016). https://digitalcommons.wustl.edu/open_access_pubs/5207 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Authors Barbara Muz, Rachel N. Ghazarian, Monica Ou, Micha J. Luderer, Hubert D. Kusdono, and Abdel K. Azab This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/5207 Journal name: Drug Design, Development and Therapy Article Designation: Review Year: 2016 Volume:
    [Show full text]
  • Primary Plasma Cell Leukemia: a Practical Approach to Diagnosis and Clinical Management
    PRIMARY PLASMA CELL LEUKEMIA: A PRACTICAL APPROACH TO DIAGNOSIS AND CLINICAL MANAGEMENT Primary Plasma Cell Leukemia: A Practical Approach to Diagnosis and Clinical Management Wilson I. Gonsalves, MD Abstract clonal plasma cells. Although Gluzinski and Reichenstein were the 1 Primary plasma cell leukemia (pPCL) represents a rare first to describe a case of PCL back in 1906, it was Kyle and Noel but most aggressive form of multiple myeloma. Its who went on to define it as the presence of plasma cells consisting leukemic clinical characteristics, as seen by the presence of more than 20% of the differential white count in the peripheral of circulating clonal plasma cells, its unique molecular blood, or an absolute plasma cell peripheral blood count of greater 9 2 and cytogenetic aberrations, and its exceedingly poor than 2.0 x 10 cells/L. If PCL is detected at diagnosis de novo survival outcomes set it apart from traditional multiple without a prior history of MM, it is considered primary plasma cell myeloma. Recent advances in the utilization of novel leukemia (pPCL). HoWever, if PCL arises in a patient with a known agents and high-dose chemotherapy in the upfront man- history of MM, it is considered secondary PCL (sPCL). The con- agement of patients with pPCL is finally bearing fruit in dition occurs as a progressive event of the disease in 1% to 4% of 3 terms of improving survival outcomes, albeit modestly. patients with MM. With the improvement in survival experienced 4 Early recognition of pPCL in a newly diagnosed multiple by patients with MM, many are living long enough to have their myeloma patient is crucial for providing the optimal MM transform into sPCL.
    [Show full text]
  • Progression of a Solitary, Malignant Cutaneous Plasma-Cell Tumour to Multiple Myeloma in a Cat
    Case Report Progression of a solitary, malignant cutaneous plasma-cell tumour to multiple myeloma in a cat A. Radhakrishnan1, R. E. Risbon1, R. T. Patel1, B. Ruiz2 and C. A. Clifford3 1 Mathew J. Ryan Veterinary Hospital of the University of Pennsylvania, Philadelphia, PA, USA 2 Antech Diagnostics, Farmingdale, NY, USA 3 Red Bank Veterinary Hospital, Red Bank, NJ, USA Abstract An 11-year-old male domestic shorthair cat was examined because of a soft-tissue mass on the left tarsus previously diagnosed as a malignant extramedullary plasmacytoma. Findings of further diagnostic tests carried out to evaluate the patient for multiple myeloma were negative. Five Keywords hyperproteinaemia, months later, the cat developed clinical evidence of multiple myeloma based on positive Bence monoclonal gammopathy, Jones proteinuria, monoclonal gammopathy and circulating atypical plasma cells. This case multiple myeloma, pancytopenia, represents an unusual presentation for this disease and documents progression of an plasmacytoma extramedullary plasmacytoma to multiple myeloma in the cat. Introduction naemia, although it also can occur with IgG or IgA Plasma-cell neoplasms are rare in companion ani- hypersecretion (Matus & Leifer, 1985; Dorfman & mals. They represent less than 1% of all tumours in Dimski, 1992). Clinical signs of hyperviscosity dogs and are even less common in cats (Weber & include coagulopathy, neurologic signs (dementia Tebeau, 1998). Diseases represented in this category and ataxia), dilated retinal vessels, retinal haemor- of neoplasia include multiple myeloma (MM), rhage or detachment, and cardiomyopathy immunoglobulin M (IgM) macroglobulinaemia (Dorfman & Dimski, 1992; Forrester et al., 1992). and solitary plasmacytoma (Vail, 2001). These con- Coagulopathy can result from the M-component ditions can result in an excess secretion of Igs interfering with the normal function of platelets or (paraproteins or M-component) which produce a clotting factors.
    [Show full text]
  • A Case of Rare Subtype of Multiple Myeloma: Secondary Plasma Cell Leukemia Author Affiliations Are Listed at the End of This Article
    Sanwal et al. HCA Healthcare Journal of Medicine (2021) 2:1 https://doi.org/10.36518/2689-0216.1114 Case Report A Case of Rare Subtype of Multiple Myeloma: Secondary Plasma Cell Leukemia Author affiliations are listed at the end of this article. Chandra Sanwal, DO,1 Aftab Mahmood, MD,1 Michael Bailey, MD,2 Krutika Patel, MD,1 Antonio Guzman, MD1 Correspondence to: Chandra Sanwal, DO Abstract Corpus Christi Medical Description Center Plasma cell leukemia is a rare, aggressive form of multiple myeloma with the presence of 7101 S Padre Island Dr circulating plasma cells in the peripheral blood. There are two types of plasma cell leukemia, Corpus Christi, TX 78412 primary and secondary, depending on if there was previous evidence of multiple myeloma. The diagnostic criterion of plasma cell leukemia is based on a percentage (>20%) or an abso- (chandrasanwal7@gmail. lute number of (≥2 x 109/L) plasma cells in the peripheral circulation. We present the clinical com) course of a rare case of secondary plasma cell leukemia in a patient from the time of initial diagnosis of multiple myeloma, its remission period of about 5 years, and its final progres- sion into refractory secondary plasma cell leukemia. This case report details the patient’s presenting symptoms, pertinent laboratory and diagnostic imaging findings, and histopa- thology of peripheral blood and bone marrow. This case report presents a chronological comparison of key laboratory findings that manifest the progression of multiple myeloma into secondary plasma cell leukemia. It also offers a brief review of the literature for the diagnosis and treatment of plasma cell leukemia.
    [Show full text]
  • Plasma Cell Leukemia – Facts and Controversies: More Questions Than Answers?
    Clinical Hematology International Vol. 2(4); December (2020), pp. 133–142 DOI: https://doi.org/10.2991/chi.k.200706.002; eISSN 2590-0048 https://www.atlantis-press.com/journals/chi/ Review Plasma Cell Leukemia – Facts and Controversies: More Questions than Answers? Anna Suska1, David H. Vesole2, Jorge J. Castillo3, Shaji K. Kumar4, Hari Parameswaran5, Maria V. Mateos6, Thierry Facon7, Alessandro Gozzetti8, Gabor Mikala9, Marta Szostek1, Joseph Mikhael10, Roman Hajek11, Evangelos Terpos12, Artur Jurczyszyn1,* 1Department of Hematology, Jagiellonian University Medical College, Kopernika 17, Krakow 31-501, Poland 2The John Theurer Cancer Center at Hackensack UMC, Hackensack, NJ, USA 3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA 4Division of Hematology, Mayo Clinic, Rochester, MN, USA 5Medical College of Wisconsin, Milwaukee, WI, USA 6Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (CAUSA/IBSAL), Salamanca, Spain 7Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France 8Division of Hematology and Transplants, University of Siena, Siena, Italy 9Department of Hematology and Stem Cell Transplantation, South-Pest Central Hospital, Natl. Inst. Hematol. Infectol, Budapest, Hungary 10Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona, USA 11University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic 12Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece ARTICLE INFO ABSTRACT Article History Plasma cell leukemia (PCL) is an aggressive hematological malignancy characterized by an uncontrolled clonal proliferation of Received 07 April 2020 plasma cells (PCs) in the bone marrow and peripheral blood. PCL has been defined by an absolute number of circulating PCs Accepted 01 June 2020 exceeding 2.0 × 109/L and/or >20% PCs in the total leucocyte count.
    [Show full text]
  • Ninlaro® (Ixazomib)
    Ninlaro® (ixazomib) (Oral) Document Number: IC-0261 Last Review Date: 10/26/2020 Date of Origin: 12/04/2015 Dates Reviewed: 12/04/2015, 10/2016, 10/2017, 10/2018, 11/2019, 11/2020 I. Length of Authorization 6,7 Coverage will be provided for six months and may be renewed unless otherwise specified. Waldenström Macroglobulinemia: Initial coverage will be provided for 6 months consisting of six 4-week cycles (6 doses) and may be renewed up to a maximum of six 8-week cycles (6 doses) Systemic Light Amyloidosis: Coverage may be renewed up to a maximum of twelve 4-week cycles (12 doses) II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: 2.3 mg capsule: 3 capsules per 28 days 3 mg capsule: 3 capsules per 28 days 4 mg capsule: 3 capsules per 28 days B. Max Units (per dose and over time) [HCPCS Unit]: 12 mg per 28 days III. Initial Approval Criteria 1 Coverage is provided in the following conditions: Patient is at least 18 years of age; AND Universal Criteria 1 Patient will avoid concomitant use with strong CYP3A inducers (e.g., rifampin, phenytoin, carbamazepine, St. John’s Wort, etc.); AND Multiple Myeloma† Ф 1-3 Used as initial therapy; AND Proprietary & Confidential © 2020 Magellan Health, Inc. o Used in combination with lenalidomide and dexamethasone in patients who are not transplant candidates; OR o Used in combination with cyclophosphamide and dexamethasone in patients who are transplant candidates; OR Used as maintenance therapy; AND o Used as single agent therapy in patients who are transplant candidates; AND .
    [Show full text]
  • An Unfortunate Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Change (POEMS)
    Open Access Case Report DOI: 10.7759/cureus.1086 An Unfortunate Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Change (POEMS) Faraz Afridi 1 , Jorge Otoya 2 , Samantha F. Bunting 3 , Gerard Chaaya 1 1. Internal Medicine, University of Central Florida College of Medicine 2. Hematology and Medical Oncology, Osceola Regional Medical Center 3. University of Central Florida College of Medicine Corresponding author: Faraz Afridi, [email protected] Abstract POEMS syndrome is an acronym for polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes, which is a rare paraneoplastic disease of monoclonal plasma cells. A mandatory criterion to diagnose POEMS syndrome is the presence of a monoclonal plasma cell dyscrasia in which plasma cell leukemia is the most aggressive form. Early identification of the features of the POEMS syndrome is critical for patients to identify an underlying plasma cell dyscrasias and to reduce the morbidity and mortality of the disease by providing early therapy. We present a case of a 64-year-old male who presented with non-specific symptoms and was found to have primary plasma cell leukemia, which was part of his unfortunate POEMS syndrome. Categories: Endocrinology/Diabetes/Metabolism, Internal Medicine, Oncology Keywords: poems syndrome, plasma cell leukemia Introduction Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, also known as Crow-Fukase syndrome is a rare paraneoplastic disease of monoclonal plasma cells which was first reported in 1956 [1]. The acronym of “POEMS” was derived in 1980 by Bardwick and colleagues on the basis of the five unique characteristic features [2]. The POEMS syndrome can present with plasma cell dyscrasias and therefore early identification of this syndrome may aid in the clinical course of plasma cell leukemias and other plasma cell proliferative disorders.
    [Show full text]
  • A Diagnostic Conundrum
    Open Access Case Report DOI: 10.7759/cureus.16832 Leucocytoclastic Vasculitis, Cryoglobulinemia, or Plasma Cell Leukemia: A Diagnostic Conundrum Hycienth Ahaneku 1 , Ruby Gupta 1 , Nwabundo Anusim 1 , Chukwuemeka A. Umeh 2 , Joseph Anderson 3 , Ishmael Jaiyesimi 1 1. Hematology and Oncology, Beaumont Health, Royal Oak, USA 2. Internal Medicine, Beaumont Health, Hemet, USA 3. Hematology and Oncology, Beaumont Health, Royal Oak, USA Corresponding author: Hycienth Ahaneku, [email protected] Abstract Plasma cell leukemia is rare and could be life-threatening. Even rarer and equally life-threatening is cryoglobulinemia. Both of them occurring together paints a grim clinical picture. We present the case of a 63-year-old male with plasma cell leukemia complicated by cryoglobulinemia with skin lesions. The report briefly reviews the clinical and diagnostic characteristics of plasma cell leukemia and well as available treatment options. It also highlights the need to consider non-chemotherapy-based regimens and clinical trials in the care of plasma cell leukemia patients. Categories: Oncology, Rheumatology, Hematology Keywords: plasma cell leukemia, cryoglobulinemia, multiple myeloma, bortezomib, lenalidomide, autologous stem cell transplant Introduction Plasma cell dyscrasias are a group of hematologic malignancies characterized by clonal proliferation of plasma cells. They cover a spectrum ranging from the premalignant monoclonal gammopathy of undetermined significance (MGUS) to the more aggressive multiple myeloma (MM) and plasma cell leukemia (PCL). PCL is often seen as the most aggressive plasma cell neoplasm. PCL accounts for less than 4% of plasma cell neoplasms and its population incidence is about one in a million, making it one of the rarest of plasma cell neoplasms [1].
    [Show full text]
  • Flow Cytometric Immunophenotyping for Hematologic Neoplasms
    From www.bloodjournal.org by on October 28, 2010. For personal use only. 2008 111: 3941-3967 Prepublished online Jan 15, 2008; doi:10.1182/blood-2007-11-120535 Flow cytometric immunophenotyping for hematologic neoplasms Fiona E. Craig and Kenneth A. Foon Updated information and services can be found at: http://bloodjournal.hematologylibrary.org/cgi/content/full/111/8/3941 Articles on similar topics may be found in the following Blood collections: Immunobiology (4229 articles) Neoplasia (4217 articles) Free Research Articles (1001 articles) Review Articles (294 articles) Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/misc/rights.dtl#repub_requests Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/misc/rights.dtl#reprints Information about subscriptions and ASH membership may be found online at: http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published semimonthly by the American Society of Hematology, 1900 M St, NW, Suite 200, Washington DC 20036. Copyright 2007 by The American Society of Hematology; all rights reserved. From www.bloodjournal.org by on October 28, 2010. For personal use only. Review article Flow cytometric immunophenotyping for hematologic neoplasms Fiona E. Craig1 and Kenneth A. Foon2 1Division of Hematopathology, Department of Pathology, and 2Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, PA Flow cytometric immunophenotyping re- plasms, including lymphoma, chronic lym- should flow cytometric immunophenotyp- mains an indispensable tool for the diag- phoid leukemias, plasma cell neoplasms, ing be applied? The recent Bethesda Interna- nosis, classification, staging, and moni- acute leukemia, paroxysmal nocturnal he- tional Consensus Conference on flow cyto- toring of hematologic neoplasms.
    [Show full text]
  • Plasma Cell Leukemia Remains Like an Incurable Disease? a Rare Presentation
    L al of euk rn em u i o a J Journal of Leukemia Magalhaes et al., J Leuk 2015, 2:4 ISSN: 2329-6917 DOI: 10.4172/2329-6917.1000157 Case Report Open Access Plasma Cell Leukemia Remains Like an Incurable Disease? A Rare Presentation of an Aggressive Case of Secondary Plasma Cell Leukemia Alessandra Gabrielly Magalhães1, James Chagas Almeida1, RenataCordeiro de Araujo1, Jaílson Ferreira Silva1,4, Clésia Abreu Figueiredo Brandão2, Paloma Lys de Medeiros3, Jeymesson Raphael Cardoso Vieira3, Isvania Maria Serafim da Silva4 and Luiz Arthur Calheiros Leite4* 1Graduate student, Center of Biological Sciences, Federal University of Pernambuco, UFPE, Recife, PE, Brazil 2Hematology and HemotherapyCenter, HEMOAL, AL, Brazil 3Department of Histology and Embryology, Center of Biological Sciences, UFPE, Recife, Pernambuco, Brazil 4Department of Biophysics and Radiobiology, Center of Biological Sciences, UFPE, Recife, PE, Brazil *Corresponding author: Luiz Arthur Calheiros, Leite, Laboratory of Cell Biology UFPE, Recife, PE, Brazil, Tel: +55-81-21268535; E-mail: [email protected] Rec date:May 21, 2014, Acc date:Sep 10, 2014; Pub date:Sep23, 2014 Copyright: © 2014 Magalhaes AG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Secondary plasma cell leukemia is an aggressive variant of multiple myeloma characterized by the presence of more than 2×109/L plasma cells on peripheral blood. We reported an unusual presentation of this entity. The diagnosis of secondary plasma cell leukemia was done by cytological and immunophenotypic characteristics of plasma cells.
    [Show full text]
  • Plasma Cell Myeloma, Plasmacytoma
    Plasma Cell Neoplasms Plasma cell neoplasms: definition • Immunosecretory disorders result from the expansion of a single clone of immunoglobulin secreting, terminally differentiated, end-stage B- cells. • These monoclonal proliferations of either plasma cells or plasmocytoid lymphocytes are characterised by secretion of a single homogeneous immunoglobulin product known as the M-component or monoclonal component. Plasma cell neoplasms: definition • The prominence of the M-component in serum and urine protein electrophoresis (SPE, UPE) has led to various designations for these disorders including monoclonal gammopathies, dysproteinemias and paraproteinemias. • The M-components, although monoclonal, may be seen in both malignant conditions (plasma cell myeloma and Waldenström macroglobulinemia) and benign or premalignant disorders (MGUS). Plasma cell neoplasms: definition • Among these gammopathies are a number of clinicopathological entities, some being primarily plasmacytic, including plasma cell (multiple) myeloma and plasmacytoma; while others contain also lymphocytes, including the heavy chain diseases and Waldenström macroglobulinemia. Plasma cell neoplasms: definition • Variants of plasma cell myeloma include syndromes defined by the consequence of tissue immunoglobulin deposition, including (1) primary amyloidosis (AL), and (2) light and heavy chain deposition diseases. Plasma Cell Myeloma Plasma Cell Myeloma: Definition • Bone marrow based, multifocal plasma cell neoplasm characterised by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. • The disease spans a spectrum from localized, smoldering or indolent to aggressive, disseminated forms with plasma cell infiltration of various organs, plasma cell leukemia and deposition of abnormal Ig chains in tissues. Plasma Cell Myeloma: Definition • The diagnosis is based on a combination of pathological, radiological, and clinical features.
    [Show full text]
  • Concomitant Diagnosis of Plasma Cell Leukemia in Patient with JAK2 Positive Myeloproliferative Neoplasm
    Thomas Jefferson University Jefferson Digital Commons Division of Internal Medicine Faculty Papers & Presentations Division of Internal Medicine 1-1-2020 Case Report: Concomitant Diagnosis of Plasma Cell Leukemia in Patient With JAK2 Positive Myeloproliferative Neoplasm. Christine J Kurian Thomas Jefferson University Colin Thomas Thomas Jefferson University Sarah Houtmann Thomas Jefferson University Thomas Klumpp Thomas Jefferson University Follow this and additional works at: https://jdc.jefferson.edu/internalfp Adam Finn Binder Thomas Part ofJeff theerson Internal Univ Medicineersity Commons Let us know how access to this document benefits ouy Recommended Citation Kurian, Christine J; Thomas, Colin; Houtmann, Sarah; Klumpp, Thomas; and Binder, Adam Finn, "Case Report: Concomitant Diagnosis of Plasma Cell Leukemia in Patient With JAK2 Positive Myeloproliferative Neoplasm." (2020). Division of Internal Medicine Faculty Papers & Presentations. Paper 37. https://jdc.jefferson.edu/internalfp/37 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Division of Internal Medicine Faculty Papers & Presentations by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [email protected]. CASE REPORT published: 27 August 2020 doi: 10.3389/fonc.2020.01497 Case Report: Concomitant Diagnosis of Plasma Cell Leukemia in Patient With JAK2 Positive Myeloproliferative Neoplasm Christine J.
    [Show full text]